This announcement is a separate document:
泰格医药：北京市嘉源律师事务所关于杭州泰格医药科技股份有限公司2023年度股东大会、2024年第二次A股类别股东会议及2024年第二次H股类别股东会议的法律意见书
Hangzhou Tigermed Consulting: Legal Opinions of Beijing Jiayuan Law Firm on the 2023 Annual General Meeting of Shareholders of Hangzhou Tiger Pharmaceutical Technology Co., Ltd., the 2nd Class A Shareholders' Meeting in 2024, and the 2nd Class H Shareholders' Meeting in 2024
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.